Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis

Journal of Neurology Neurosurgery and Psychiatry

Volumn 70, Issue 4, 2001, Pages 544-547

  Brex, P A ^a   Leary, S M ^a   O'Riordan, J I ^a   Miszkiel, K A ^b   Plant, G T ^c   Thompson, A J ^a   Miller, D H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

Clinically isolated syndromes; Multiple sclerosis; Spinal cord atrophy

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATION; DIAGNOSTIC IMAGING; DISEASE SEVERITY; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SPINAL CORD ATROPHY;

ADOLESCENT; ADULT; ATROPHY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SPINAL CORD; SYNDROME;

EID: 0035059818     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.70.4.544     Document Type: Article

References (15)

1. Losseff NA, Webb SL, O'Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996;119:701-8.
2. Stevenson VL, Leary SM, Losseff NA, et al. Spinal cord atrophy and disability in MS: a longitudinal study. Neurology 1998;51:234-8.
3. Liu C, Edwards S, Gong Q, Roberts N. Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999;66:323-30.
4. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46:296-304.
5. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338:278-85
6. Ganter P, Prince C, Esiri MM. Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol Appl Neurobiol 1999;25:459-67.
7. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998;121:495-503.
8. Leary SM, Parker GJ, Stevenson VL, et el. Reproducibility of magnetic resonance imaging measurements of spinal cord atrophy: the role of quality assurance. Magn Reson Imaging 1999;17:773-6.
9. Brex PA, O'Riordan JI, Miszkiel KA, et al. Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology 1999;53:1184-90
10. Brex PA, Jenkins R, Fox NC, et al. Detection of ventricular enlargement in patients at the earliest clinical stage of multiple sclerosis. Neurology 2000;54:1689-91
11. Evangelou N, Esiri MM, Smith S, et al. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000;47:391-5.
12. Brex PA, Gomez-Anson B, Parker GJ, et al. Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Sci 1999;166:16-22.
13. Tourbah A, Stievenart JL, Abanou A, et al. Normal-appearing white matter in optic neuritis and multiple sclerosis: a comparative proton spectroscopy study. Neuroradiology 1999;41:738-43.
14. Iannucci G, Tortorella C, Rovaris M, et al. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. Am J Neuroradiol 2000;21:1034-8.
15. Kaiser JS, Grossman RI, Polansky M, et al. Magnetization transfer histogram analysis of monosymptomatic episodes of neurologic dysfunction: preliminary findings. Am J Neuroradiol 2000;21:1043-7.